PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
作者： Fotios Loupakis , Luca Pollina , Irene Stasi , Annamaria Ruzzo , Mario Scartozzi
关键词:
摘要: Purpose PTEN, AKT, and KRAS are epidermal growth factor receptor (EGFR) downstream regulators. mutations confer resistance to cetuximab. This retrospective study investigated the role of PTEN loss, AKT phosphorylation, on activity cetuximab plus irinotecan in patients with metastatic colorectal cancer (mCRC). Patients Methods A cohort irinotecan-refractory mCRC who were treated was tested for immunoreactivity (ie, immunohistochemistry; IHC), pAKT IHC, mutations. Analyses performed both primary tumors related metastases, association among mutational results, treatment outcomes investigated. Results One-hundred two eligible. Ninety-six tumors, 59 53 paired samples available. Forty-nine (58% assessable samples) had a preserved expression (PTEN-positive), whereas 35 (40% pAKT-positive. ...
elsevier.com
sci-hub.se 参考文章(40)
Sarah Edkins, Sarah O'Meara, Adrian Parker, Claire Stevens, Marcelo Reis, Siân Jones, Chris Greenman, Helen Davies, Gillian Dalgliesh, Simon Forbes, Chris Hunter, Raffaella Smith, Philip Stephens, Peter Goldstraw, Andrew Nicholson, Tsun Leung Chan, Victor E Velculescu, Siu Tsan Yuen, Suet Yi Leung, Michael R Stratton, P Andrew Futreal, Recurrent KRAS Codon 146 Mutations in Human Colorectal Cancer Cancer Biology & Therapy. ,vol. 5, pp. 928- 932 ,(2006) , 10.4161/CBT.5.8.3251
Antonio Di Cristofano, Pier Paolo Pandolfi, The Multiple Roles of PTEN in Tumor Suppression Cell. ,vol. 100, pp. 387- 390 ,(2000) , 10.1016/S0092-8674(00)80674-1
F. Cappuzzo, E. Magrini, G. L. Ceresoli, S. Bartolini, E. Rossi, V. Ludovini, V. Gregorc, C. Ligorio, A. Cancellieri, S. Damiani, A. Spreafico, C. T. Paties, L. Lombardo, C. Calandri, G. Bellezza, M. Tonato, L. Crino, Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute. ,vol. 96, pp. 1133- 1141 ,(2004) , 10.1093/JNCI/DJH217
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
Aurel Perren, Liang-Ping Weng, Alexander H. Boag, Ulricke Ziebold, Kosha Thakore, Patricia L.M. Dahia, Paul Komminoth, Jacqueline A. Lees, Lois M. Mulligan, George L. Mutter, Charis Eng, Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the Breast American Journal of Pathology. ,vol. 155, pp. 1253- 1260 ,(1999) , 10.1016/S0002-9440(10)65227-3
Xiao-Ping Zhou, Anu Loukola, Reijo Salovaara, Minna Nystrom-Lahti, Päivi Peltomäki, Albert de la Chapelle, Lauri A. Aaltonen, Charis Eng, PTEN Mutational Spectra, Expression Levels, and Subcellular Localization in Microsatellite Stable and Unstable Colorectal Cancers American Journal of Pathology. ,vol. 161, pp. 439- 447 ,(2002) , 10.1016/S0002-9440(10)64200-9
M Scartozzi, I Bearzi, R Berardi, A Mandolesi, C Pierantoni, S Cascinu, Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. British Journal of Cancer. ,vol. 97, pp. 92- 97 ,(2007) , 10.1038/SJ.BJC.6603847
Carmen J. Marsit, Shichun Zheng, Kenneth Aldape, Philip W. Hinds, Heather H. Nelson, John K. Wiencke, Karl T. Kelsey, PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Human Pathology. ,vol. 36, pp. 768- 776 ,(2005) , 10.1016/J.HUMPATH.2005.05.006
John Mendelsohn, Jose Baselga, Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer Journal of Clinical Oncology. ,vol. 21, pp. 2787- 2799 ,(2003) , 10.1200/JCO.2003.01.504
Y Kokubo, A Gemma, R Noro, M Seike, K Kataoka, K Matsuda, T Okano, Y Minegishi, A Yoshimura, M Shibuya, S Kudoh, Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). British Journal of Cancer. ,vol. 92, pp. 1711- 1719 ,(2005) , 10.1038/SJ.BJC.6602559